MediciNova, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of novel, high-quality small molecule therapeutics. MediciNova currently has six compounds in development for seven different indications, including four programs in advanced clinical testing for the treatment of asthma, Generalized Anxiety Disorder, interstitial cystitis and multiple sclerosis.
